FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011913908> ?p ?o ?g. }

• W2011913908 endingPage "1283" @default.
• W2011913908 startingPage "1274" @default.
• W2011913908 abstract "<b><i>Objective: </i></b> To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN). <b><i>Methods: </i></b> The authors conducted a multicenter, parallel-group, double-blind, placebo-controlled, 8-week, randomized clinical trial in PHN, defined as pain for 3 or more months following herpes zoster rash healing. Patients (n = 173) were randomized to treatment with pregabalin or placebo. Patients randomized to pregabalin received either 600 mg/day (creatinine clearance > 60 mL/min) or 300 mg/day (creatinine clearance 30 to 60 mL/min). The primary efficacy measure was the mean of the last seven daily pain ratings. Secondary endpoints included additional pain ratings, sleep interference, quality of life, mood, and patient and clinician ratings of global improvement. <b><i>Results: </i></b> Pregabalin-treated patients had greater decreases in pain than patients treated with placebo (endpoint mean scores 3.60 vs 5.29, <i>p</i> = 0.0001). Pain was significantly reduced in the pregabalin-treated patients after the first full day of treatment and throughout the study, and significant improvement on the McGill Pain Questionnaire total, sensory, and affective pain scores was also found. The proportions of patients with ≥30% and ≥50% decreases in mean pain scores were greater in the pregabalin than in the placebo group (63% vs 25% and 50% vs 20%, <i>p</i> = 0.001). Sleep also improved in patients treated with pregabalin compared to placebo (<i>p</i> = 0.0001). Both patients and clinicians were more likely to report global improvement with pregabalin than placebo (<i>p</i> = 0.001). Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity. <b><i>Conclusions: </i></b> Treatment of PHN with pregabalin is safe, efficacious in relieving pain and sleep interference, and associated with greater global improvement than treatment with placebo." @default.
• W2011913908 created "2016-06-24" @default.
• W2011913908 creator A5020080352 @default.
• W2011913908 creator A5048043818 @default.
• W2011913908 creator A5058953436 @default.
• W2011913908 creator A5062558520 @default.
• W2011913908 creator A5068025809 @default.
• W2011913908 creator A5073326142 @default.
• W2011913908 creator A5073341903 @default.
• W2011913908 creator A5086017966 @default.
• W2011913908 date "2003-04-22" @default.
• W2011913908 modified "2023-10-16" @default.
• W2011913908 title "Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial" @default.
• W2011913908 cites W1535948728 @default.
• W2011913908 cites W1569947967 @default.
• W2011913908 cites W1570776100 @default.
• W2011913908 cites W1902482691 @default.
• W2011913908 cites W1980564212 @default.
• W2011913908 cites W1997048153 @default.
• W2011913908 cites W2001638015 @default.
• W2011913908 cites W2006733509 @default.
• W2011913908 cites W2008857257 @default.
• W2011913908 cites W2014670473 @default.
• W2011913908 cites W2016027137 @default.
• W2011913908 cites W2027053525 @default.
• W2011913908 cites W2037208185 @default.
• W2011913908 cites W2037377025 @default.
• W2011913908 cites W2039982019 @default.
• W2011913908 cites W2040475489 @default.
• W2011913908 cites W2054507992 @default.
• W2011913908 cites W2055967275 @default.
• W2011913908 cites W2057983296 @default.
• W2011913908 cites W2073543688 @default.
• W2011913908 cites W2082940913 @default.
• W2011913908 cites W2088937042 @default.
• W2011913908 cites W2091011313 @default.
• W2011913908 cites W2098869600 @default.
• W2011913908 cites W2102023851 @default.
• W2011913908 cites W2103289578 @default.
• W2011913908 cites W2122540356 @default.
• W2011913908 cites W2126855798 @default.
• W2011913908 cites W2132309748 @default.
• W2011913908 cites W2134255029 @default.
• W2011913908 cites W2136743000 @default.
• W2011913908 cites W2138407894 @default.
• W2011913908 cites W2150235997 @default.
• W2011913908 cites W2150775151 @default.
• W2011913908 cites W2156795463 @default.
• W2011913908 cites W33374171 @default.
• W2011913908 doi "https://doi.org/10.1212/01.wnl.0000055433.55136.55" @default.
• W2011913908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12707429" @default.
• W2011913908 hasPublicationYear "2003" @default.
• W2011913908 type Work @default.
• W2011913908 sameAs 2011913908 @default.
• W2011913908 citedByCount "730" @default.
• W2011913908 countsByYear W20119139082012 @default.
• W2011913908 countsByYear W20119139082013 @default.
• W2011913908 countsByYear W20119139082014 @default.
• W2011913908 countsByYear W20119139082015 @default.
• W2011913908 countsByYear W20119139082016 @default.
• W2011913908 countsByYear W20119139082017 @default.
• W2011913908 countsByYear W20119139082018 @default.
• W2011913908 countsByYear W20119139082019 @default.
• W2011913908 countsByYear W20119139082020 @default.
• W2011913908 countsByYear W20119139082021 @default.
• W2011913908 countsByYear W20119139082022 @default.
• W2011913908 countsByYear W20119139082023 @default.
• W2011913908 crossrefType "journal-article" @default.
• W2011913908 hasAuthorship W2011913908A5020080352 @default.
• W2011913908 hasAuthorship W2011913908A5048043818 @default.
• W2011913908 hasAuthorship W2011913908A5058953436 @default.
• W2011913908 hasAuthorship W2011913908A5062558520 @default.
• W2011913908 hasAuthorship W2011913908A5068025809 @default.
• W2011913908 hasAuthorship W2011913908A5073326142 @default.
• W2011913908 hasAuthorship W2011913908A5073341903 @default.
• W2011913908 hasAuthorship W2011913908A5086017966 @default.
• W2011913908 hasConcept C126322002 @default.
• W2011913908 hasConcept C14184104 @default.
• W2011913908 hasConcept C142724271 @default.
• W2011913908 hasConcept C168563851 @default.
• W2011913908 hasConcept C204787440 @default.
• W2011913908 hasConcept C27081682 @default.
• W2011913908 hasConcept C2776432500 @default.
• W2011913908 hasConcept C2776468701 @default.
• W2011913908 hasConcept C2777107010 @default.
• W2011913908 hasConcept C2778866549 @default.
• W2011913908 hasConcept C2780016216 @default.
• W2011913908 hasConcept C42219234 @default.
• W2011913908 hasConcept C71924100 @default.
• W2011913908 hasConceptScore W2011913908C126322002 @default.
• W2011913908 hasConceptScore W2011913908C14184104 @default.
• W2011913908 hasConceptScore W2011913908C142724271 @default.
• W2011913908 hasConceptScore W2011913908C168563851 @default.
• W2011913908 hasConceptScore W2011913908C204787440 @default.
• W2011913908 hasConceptScore W2011913908C27081682 @default.
• W2011913908 hasConceptScore W2011913908C2776432500 @default.
• W2011913908 hasConceptScore W2011913908C2776468701 @default.
• W2011913908 hasConceptScore W2011913908C2777107010 @default.

• next